The Patent Finder
CR

Cancer Research Technology Limited

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

109 patents currently held

33 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next US patent term in the Cancer Research Technology Limited portfolio ends in Dec 2026, and more of its terms end in 2036 (14) than in any other year. from the record

Of the 33 now held by other companies, 6 name Windtree Therapeutics Inc. as their current owner, and 27 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
15
Ending by 2030
Dec 2026
Next term end
75
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Isoindolinone Inhibitors of the MDM2-P53 Interaction Having Anticancer Activity US 10,544,132
Cited by 16 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2036. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Ends no later than Sep 2036 · Medium confidence
Also notable
Heterocyclic Compounds as Ret Kinase Inhibitors US 10,954,241
Cited by 10 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2037. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Ends no later than Apr 2037 · Medium confidence
Also notable
Ortho-Condensed Pyridine and Pyrimidine Derivatives (E.G., Purines) as Protein Kinases Inhibitors US 8,546,407
The most cited patent in this portfolio, cited by 28 later US patents, top 25% of utility patents granted in 2013 in our data. Protection runs to 2031.
Ends Jan 2031 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 3 fees due Dec 9 to 20, 2026 · next Dec 9
  • 1 fee due Jan 11, 2027
    The maintenance fee for ANTI-CD25 for Tumour Specific Cell Depletion (US 11,697,688) comes due Jan 11, 2027. Unpaid by Jul 12, 2027, it lapses early.
  • 5 fees due Mar 3 to 26, 2027 · next Mar 3
  • 5 fees due Apr 1 to 30, 2027 · next Apr 1
  • 3 fees due May 14 to 19, 2027 · next May 14
  • 3 fees due Jun 10 to 26, 2027 · next Jun 10
  • 5 fees due Jul 7 to 30, 2027 · next Jul 7
  • 2 fees due Aug 9 to 13, 2027 · next Aug 9
  • 2 fees due Sep 5, 2027
  • 3 fees due Nov 5 to 19, 2027 · next Nov 5

Which patents, and when each one lapses · Pro

Recent changes

  • 2 of the patents on this record were granted since Aug 24, 2026
  • 1 term has ended since Aug 24, 2026

What they patent

The largest of its 75 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 8,957,195ANTI-CD19 Antibodies with Reduced Immunogenicity
In force
 · High confidence
In forceHigh confidence
US 8,258,175ISOINDOLIN-1-ONE Derivatives
In force
 · High confidence
In forceHigh confidence
US 11,208,496ANTI-CD19 Antibodies with Reduced Immunogenicity
In force
 · High confidence
In forceHigh confidence
US 9,919,023Anti-Androgen Peptides and Uses Thereof in Cancer Therapy
In force
 · High confidence
In forceHigh confidence
US 11,560,406Anti-Androgen Peptides and Uses Thereof in Cancer Therapy
In force
 · High confidence
In forceHigh confidence
US 10,072,092Methods of Use of ANTI-CD19 Antibodies with Reduced Immunogenicity
In force
 · High confidence
In forceHigh confidence
US 8,058,045PYRAZIN-2-YL-PYRIDIN-2-YL-AMINE and PYRAZIN-2-YL-PYRIMIDIN-4-YL-AMINE Compounds and Their Use
In force
 · High confidence
In forceHigh confidence
US 8,367,658PYRAZIN-2-YL-PYRIDIN-2-YL-AMINE and PYRAZIN-2-YL-PYRIMIDIN-4-YL-AMINE Compounds and Their Use
In force
 · High confidence
In forceHigh confidence
US 9,012,633[1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use
In force
 · High confidence
In forceHigh confidence
US 8,796,293Purine and Deazapurine Derivatives as Pharmaceutical Compounds
In force
 · High confidence
In forceHigh confidence
10 of 109 patents shown.
Pro members see all 109.
Pro members: see all 109 patents
Also on record, not counted in the 109: 33 patents in force now held by others · 137 patents ended · 61 applications pending · 119 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited